| The following article features coverage from the American Society of Clinical Oncology 2020 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage. |
Bintrafusp alfa appears to yield durable responses in the second line among patients with high PD-L1–expressing non-small cell lung cancer (NSCLC), according to research presented at the ASCO20 Virtual Scientific Program.
An ongoing phase 1 trial (ClinicalTrials.gov Identifier: NCT02517398) of bintrafusp alfa, a transforming growth factor (TGF)-beta “trap” fused to an antibody that blocks PD-L1 — also known as an antibody-drug conjugate [ADC]) — previously showed an overall response rate (ORR) of 25%.
For this presentation, researchers highlighted long-term efficacy and safety follow-up data among patients with NSCLC receiving this first-in-class treatment.
Continue Reading
For this ongoing trial, researchers are randomly assigning patients with advanced NSCLC, unselected for PD-L1 expression, to receive bintrafusp alfa 500 mg or the recommended phase 2 dose of 1200 mg. Treatment is continued until disease progression or unacceptable toxicity.
Forty patients were assigned to each arm (80 individuals); 17 (21.3%) patients overall had received at least 2 prior therapies. No patients, however, had received prior immunotherapy.
Among the 22.7% (17 of 75 patients with evaluable data) responders, the median durations of response (DOR) were 15.3 months and 18 months in the 500 mg and 1200 mg cohorts, respectively. In the 3 ongoing responses, all had PD-L1–positive disease. Approximately 64% percent of patients had responses lasting 12 months or longer.
Grade 3 adverse events were noted in 23 (28.8%) patients; grade 4 events occurred in 2 (2.5%) patients. Only 1 further treatment discontinuation due to a treatment-related event (pruritis) was noted in this long-term analysis.
The median overall survival was 13.6 months regardless of biomarker status. Median OS was 21.7 months in patients with PD-L1–positive disease and not yet reached in the PD-L1–high disease subgroup.
“An ongoing phase 3 study is evaluating bintrafusp alfa compared with pembrolizumab as 1L treatment for patients with advanced NSCLC who have high PD-L1 expression (INTR@PID LUNG 037; NCT03631706),” the authors added on their poster.
Read more of Cancer Therapy Advisor‘s coverage of the ASCO 2021 meeting by visiting the conference page.
Reference
Cho BC, Kim TM, Vicente D, et al. Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). Poster presented at: ASCO20 Virtual Scientific Program. J Clin Oncol. 2020;38(suppl):abstr 9558.
